Tags

Type your tag names separated by a space and hit enter

Inactivation of SARS-CoV-2 and HCoV-229E in vitro by ColdZyme® a medical device mouth spray against the common cold.
J Med Virol. 2021 Mar; 93(3):1792-1795.JM

Abstract

BACKGROUND

The coronavirus disease 2019 (COVID-19) pandemic calls for effective and safe treatments. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 actively replicates in the throat, unlike SARS-CoV, and shows high pharyngeal viral shedding even in patients with mild symptoms of the disease. HCoV-229E is one of four coronaviruses causing the common cold. In this study, the efficacy of ColdZyme® (CZ-MD), a medical device mouth spray, was tested against SARS-CoV-2 and HCoV-229E in vitro. The CZ-MD provides a protective glycerol barrier containing cod trypsin as an ancillary component. Combined, these ingredients can inactivate common cold viruses in the throat and mouth. The CZ-MD is believed to act on the viral surface proteins that would perturb their entry pathway into cells. The efficacy and safety of the CZ-MD have been demonstrated in clinical trials on the common cold.

METHOD OF STUDY

The ability of the CZ-MD to inactivate SARS-CoV-2 and HCoV-229E was tested using an in vitro virucidal suspension test (ASTM E1052).

RESULTS

CZ-MD inactivated SARS-CoV-2 by 98.3% and HCoV-229E by 99.9%.

CONCLUSION

CZ-MD mouth spray can inactivate the respiratory coronaviruses SARS-CoV-2 and HCoV-229E in vitro. Although the in vitro results presented cannot be directly translated into clinical efficacy, the study indicates that CZ-MD might offer a protective barrier against SARS-CoV-2 and a decreased risk of COVID-19 transmission.

Links

PMC Free PDF

Authors+Show Affiliations

Gudmundsdottir Á
Faculty of Food Science and Nutrition, School of Health Sciences, University of Iceland, Reykjavík, Iceland. Zymetech, Reykjavík, Iceland.
Scheving R
Zymetech, Reykjavík, Iceland.
Lindberg F
Enzymatica AB, Lund, Sweden. Medical Faculty, Lund University, Lund, Sweden.
Stefansson B
Zymetech, Reykjavík, Iceland.

MeSH

Antiviral AgentsCOVID-19Common ColdCoronavirus 229E, HumanDisinfectantsGlycerolHumansSARS-CoV-2TrypsinViral ProteinsVirus InactivationCOVID-19 Drug Treatment

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32975843

Citation

Gudmundsdottir, Ágústa, et al. "Inactivation of SARS-CoV-2 and HCoV-229E in Vitro By ColdZyme® a Medical Device Mouth Spray Against the Common Cold." Journal of Medical Virology, vol. 93, no. 3, 2021, pp. 1792-1795.
Gudmundsdottir Á, Scheving R, Lindberg F, et al. Inactivation of SARS-CoV-2 and HCoV-229E in vitro by ColdZyme® a medical device mouth spray against the common cold. J Med Virol. 2021;93(3):1792-1795.
Gudmundsdottir, Á., Scheving, R., Lindberg, F., & Stefansson, B. (2021). Inactivation of SARS-CoV-2 and HCoV-229E in vitro by ColdZyme® a medical device mouth spray against the common cold. Journal of Medical Virology, 93(3), 1792-1795. https://doi.org/10.1002/jmv.26554
Gudmundsdottir Á, et al. Inactivation of SARS-CoV-2 and HCoV-229E in Vitro By ColdZyme® a Medical Device Mouth Spray Against the Common Cold. J Med Virol. 2021;93(3):1792-1795. PubMed PMID: 32975843.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Inactivation of SARS-CoV-2 and HCoV-229E in vitro by ColdZyme® a medical device mouth spray against the common cold. AU - Gudmundsdottir,Ágústa, AU - Scheving,Reynir, AU - Lindberg,Fredrik, AU - Stefansson,Bjarki, Y1 - 2020/10/14/ PY - 2020/9/1/received PY - 2020/9/21/revised PY - 2020/9/23/accepted PY - 2020/9/26/pubmed PY - 2021/3/11/medline PY - 2020/9/25/entrez KW - cell cultures KW - coronavirus KW - microbial cultures KW - respiratory tract SP - 1792 EP - 1795 JF - Journal of medical virology JO - J Med Virol VL - 93 IS - 3 N2 - BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic calls for effective and safe treatments. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 actively replicates in the throat, unlike SARS-CoV, and shows high pharyngeal viral shedding even in patients with mild symptoms of the disease. HCoV-229E is one of four coronaviruses causing the common cold. In this study, the efficacy of ColdZyme® (CZ-MD), a medical device mouth spray, was tested against SARS-CoV-2 and HCoV-229E in vitro. The CZ-MD provides a protective glycerol barrier containing cod trypsin as an ancillary component. Combined, these ingredients can inactivate common cold viruses in the throat and mouth. The CZ-MD is believed to act on the viral surface proteins that would perturb their entry pathway into cells. The efficacy and safety of the CZ-MD have been demonstrated in clinical trials on the common cold. METHOD OF STUDY: The ability of the CZ-MD to inactivate SARS-CoV-2 and HCoV-229E was tested using an in vitro virucidal suspension test (ASTM E1052). RESULTS: CZ-MD inactivated SARS-CoV-2 by 98.3% and HCoV-229E by 99.9%. CONCLUSION: CZ-MD mouth spray can inactivate the respiratory coronaviruses SARS-CoV-2 and HCoV-229E in vitro. Although the in vitro results presented cannot be directly translated into clinical efficacy, the study indicates that CZ-MD might offer a protective barrier against SARS-CoV-2 and a decreased risk of COVID-19 transmission. SN - 1096-9071 UR - https://www.unboundmedicine.com/medline/citation/32975843/Inactivation_of_SARS_CoV_2_and_HCoV_229E_in_vitro_by_ColdZyme®_a_medical_device_mouth_spray_against_the_common_cold_ DB - PRIME DP - Unbound Medicine ER -